{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"}],"units":"Participants"}],"description":"The correlation of the pharmacodynamic effects of flavopiridol on normal peripheral blood mononuclear cells (PBMCs)","groups":[{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Dose Level 1 (Flavopiridol 30 mg/m2 + 30 mg/m2)"},{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG001","title":"Dose Level 2 (Flavopiridol 30 mg/m2 + 50 mg/m2)"},{"description":"Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.","id":"OG002","title":"Dose Level 3 (Flavopiridol 50 mg/m2 + 50 mg/m2)"}],"populationDescription":"Data not available due to studies were not conducted by collaborating laboratory Investigator","reportingStatus":"POSTED","timeFrame":"Day 1","title":"Pharmacodynamic Effects of Flavopiridol on Normal Peripheral Blood Mononuclear Cells (PBMCs).","type":"SECONDARY"}